2013
Acute Treatment Toxicity and the Risk of Infection During Total Skin Electron Beam Therapy for Mycosis Fungoides
Lloyd S, Chen Z, Foss F, Girardi M, Wilson L. Acute Treatment Toxicity and the Risk of Infection During Total Skin Electron Beam Therapy for Mycosis Fungoides. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s557. DOI: 10.1016/j.ijrobp.2013.06.1475.Peer-Reviewed Original Research
1997
Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)
Quirós P, Jones G, Kacinski B, Braverman I, Heald P, Edelson R, Wilson L. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). International Journal Of Radiation Oncology • Biology • Physics 1997, 38: 1027-1035. PMID: 9276369, DOI: 10.1016/s0360-3016(97)00127-2.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDisease-free survivalT2 patientsCrude relapse rateAdjuvant therapyOverall survivalElectron beam therapyRelapse rateEntire cohortMedian disease-free survivalCutaneous T-cell lymphomaBeam therapySalvage of recurrencesAdjuvant systemic therapyEarly-stage patientsManagement of patientsT-cell lymphomaTopical nitrogen mustardDays/weekCombination of therapiesGy/dayTreatments/weekPUVA patientsMedian followSalvage therapy
1996
Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 1996, 35: 69-73. PMID: 8682967, DOI: 10.1016/s0190-9622(96)90499-5.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaComplete responseT-cell lymphomaElectron beam therapySecond courseMedian disease-free intervalThird courseAdditional coursesBeam therapyDisease-free intervalTreatment of patientsAcceptable risk profileForm of therapyMedian doseMedian survivalMild erythemaPatientsInitial courseTherapyVariety of modalitiesRisk profileEntire groupLocalized radiationExtent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy
Quiros P, Kacinski B, Wilson L. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996, 77: 1912-1917. PMID: 8646693, DOI: 10.1002/(sici)1097-0142(19960501)77:9<1912::aid-cncr23>3.0.co;2-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBody Surface AreaChemotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiotherapy DosageRadiotherapy, High-EnergyRemission InductionRetrospective StudiesSkinSkin NeoplasmsSurvival RateConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaComplete clinical responseOverall survivalSkin involvementT-cell lymphomaMedian DFSPrognostic indicatorTotal skin electron beam radiation therapyToxicity of therapyElectron beam radiation therapyBeam radiation therapyTotal skin surfaceElectron beam therapyFree survivalClinical responsePrognostic significanceTumor nodulesRadiation therapyPatientsPatient recordsTherapyDiseaseBeam therapyMonths
1995
Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy
Wilson L, Licata A, Braverman I, Edelson R, Heald P, Feldman A, Kacinski B. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1995, 32: 987-995. PMID: 7607973, DOI: 10.1016/0360-3016(95)00073-8.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDoxorubicin/cyclophosphamideCutaneous T-cell lymphoma patientsAdjuvant doxorubicin/cyclophosphamideT-cell lymphoma patientsExtracorporeal photochemotherapyComplete responseOverall survivalAdjuvant therapyElectron beam therapyAdjuvant regimenFree survivalCTCL patientsLymphoma patientsBeam therapyAddition of chemotherapyAdvanced stage CTCLClinical complete responseSystemic adjuvant therapyGood partial responseSignificant survival benefitBetter overall survivalRelapse-free survivalSoles of feetNontoxic regimenMalignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation
Licata A, Wilson L, Braverman I, Feldman A, Kacinski B. Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation. JAMA Dermatology 1995, 131: 432-435. DOI: 10.1001/archderm.1995.01690160060009.Peer-Reviewed Original ResearchTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinoma
1994
Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy
Wilson L, Cooper D, Goodrich A, Friedman N, Feldman A, Braverman I, Kacinski B. Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 28: 829-837. PMID: 8138435, DOI: 10.1016/0360-3016(94)90102-3.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapySystemic adjuvant therapyRelapse-free survivalDoxorubicin/cyclophosphamide chemotherapyShorter relapse-free survivalElectron beam therapyAdjuvant therapyDermatologic diagnosesBeam therapyCyclophosphamide chemotherapyFollicular mucinosisOverall survivalT2 patientsExtracorporeal photopheresisLymphomatoid papulosisCutaneous relapseTotal skin electron beam radiation therapyCutaneous T-cell lymphoma patientsT-cell lymphoma patientsBetter relapse-free survivalClinical complete responseCohort of patientsElectron beam radiation therapyBeam radiation therapyAdjuvant chemotherapyNovel prognostic factors predictive of prolonged relapse-free and overall survival in advanced stage CTCL (mycosis fungoides) patients treated with total skin electron beam therapy
Kacinski B, Wilson L, Quiros P, Kolenik S, Heald P, Edelson R, Braverman I. Novel prognostic factors predictive of prolonged relapse-free and overall survival in advanced stage CTCL (mycosis fungoides) patients treated with total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 268. DOI: 10.1016/0360-3016(94)90823-0.Peer-Reviewed Original ResearchAdditional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t-cell lymphoma [CTCL]
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy [TSEBT] in the retreatment of patients with cutaneous t-cell lymphoma [CTCL]. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 269. DOI: 10.1016/0360-3016(94)90825-7.Peer-Reviewed Original Research
1993
Increased incidence of malignant melanoma and other second cutaneous malignancies after total skin electron beam therapy (TSEBT) for CTCL (mycosis fungoldes)
Goodrich A, Wilson L, Braverman I, Kacinski B. Increased incidence of malignant melanoma and other second cutaneous malignancies after total skin electron beam therapy (TSEBT) for CTCL (mycosis fungoldes). International Journal Of Radiation Oncology • Biology • Physics 1993, 27: 187. DOI: 10.1016/0360-3016(93)90728-e.Peer-Reviewed Original ResearchAdjuvant Extracorporeal Photoimmunotherapy or adjuvant adriamyciwcytoxan chemotherapy both prolong survival for cutaneous T-cell lymphoma (CTCL, MYCOSIS FUNGOIDES) patients treated with total skin electron beam therapy (TSEBT).
Kacinaki B, Wilson L, Goodrich A, Edelson R, Heald P, Braverman I. Adjuvant Extracorporeal Photoimmunotherapy or adjuvant adriamyciwcytoxan chemotherapy both prolong survival for cutaneous T-cell lymphoma (CTCL, MYCOSIS FUNGOIDES) patients treated with total skin electron beam therapy (TSEBT). International Journal Of Radiation Oncology • Biology • Physics 1993, 27: 186-187. DOI: 10.1016/0360-3016(93)90727-d.Peer-Reviewed Original Research